Use of Liquid Patient Ascites Fluids as a Preclinical Model for Oncolytic Virus Activity.
Use of Liquid Patient Ascites Fluids as a Preclinical Model for Oncolytic Virus Activity.
复制标题
使用液体患者腹水作为溶瘤病毒活性的临床前模型。
DOI：
10.1007/978-1-4939-9794-7_17
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Scott EM
中科院分区：
文献类型：
--
作者：
Scott EM
溶瘤病毒疗法的转化成功将受益于临床相关离体模型的广泛使用。恶性腹水是由于扩散性癌症导致的腹膜中的液体积聚，其概括了肿瘤微环境的许多特征，使其成为研究溶瘤病毒活性的有价值的模型。在这里，我们描述了一种方法，用于分离和储存的细胞和非细胞成分的恶性腹水，然后通过流式细胞术表征的细胞部分。然后，我们概述了一个简单的实验，使用整个腹水，以评估双特异性T细胞粘附分子（BiTE）表达溶瘤腺病毒的活性。
The translational success of oncolytic virotherapies would benefit from the widespread use of clinically relevant ex vivo models. Malignant ascites, an accumulation of fluid in the peritoneum due to disseminated cancer, recapitulates many features of the tumor microenvironment, making it a valuable model for studying oncolytic virus activity. Here, we describe a method for the separation and storage of cellular and acellular components of malignant ascites, followed by flow cytometric characterization of the cellular fraction. We then outline a simple experiment using whole ascites to assess the activity of a bispecific T cell engager (BiTE)-expressing oncolytic adenovirus.